NASDAQ:IDXX - IDEXX Laboratories Stock Price, Forecast & News

IDEXX Laboratories trades on the NASDAQ under the ticker symbol "IDXX."

IDEXX Laboratories announced that its board has approved a share repurchase program on Wednesday, February 12th 2020, which authorizes the company to repurchase 5,000,000 outstanding shares, according to EventVestor. This repurchase authorization authorizes the company to buy shares of its stock through open market purchases. Shares repurchase programs are often a sign that the company's management believes its stock is undervalued.

IDEXX Laboratories, Inc. (NASDAQ:IDXX) posted its quarterly earnings data on Friday, January, 31st. The company reported $1.04 earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of $0.91 by $0.13. The firm earned $605.50 million during the quarter, compared to the consensus estimate of $600.60 million. The firm's quarterly revenue was up 10.2% on a year-over-year basis. During the same period in the previous year, the firm earned $0.98 earnings per share. View IDEXX Laboratories' Earnings History.

IDEXX Laboratories is scheduled to release their next quarterly earnings announcement on Wednesday, May 6th 2020. View Earnings Estimates for IDEXX Laboratories.

IDEXX Laboratories updated its FY20 earnings guidance on Friday, January, 31st. The company provided EPS guidance of $5.42-5.58 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $5.41. The company issued revenue guidance of $2.62-2.66 billion, compared to the consensus revenue estimate of $2.63 billion.

6 equities research analysts have issued 12 month target prices for IDEXX Laboratories' stock. Their forecasts range from $277.00 to $310.00. On average, they expect IDEXX Laboratories' stock price to reach $293.33 in the next twelve months. This suggests a possible upside of 1.6% from the stock's current price. View Analyst Price Targets for IDEXX Laboratories.

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for IDEXX Laboratories in the last year. There are currently 1 hold rating and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for IDEXX Laboratories.

Media stories about IDXX stock have been trending somewhat positive on Monday, according to InfoTrie Sentiment Analysis. InfoTrie identifies positive and negative press coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. IDEXX Laboratories earned a media sentiment score of 1.8 on InfoTrie's scale. They also assigned news stories about the company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the stock's share price in the immediate future. View News Stories for IDEXX Laboratories.

IDEXX Laboratories saw a decline in short interest during the month of January. As of January 31st, there was short interest totalling 1,210,000 shares, a decline of 6.9% from the January 15th total of 1,300,000 shares. Based on an average trading volume of 507,000 shares, the short-interest ratio is currently 2.4 days. Approximately 1.4% of the company's shares are short sold. View IDEXX Laboratories' Current Options Chain.

Some companies that are related to IDEXX Laboratories include Abbott Laboratories (ABT), ABIOMED (ABMD), CONMED (CNMD), ProShares UltraShort DJ-UBS Commodity (CMD), Synthorx (THOR), AtriCure (ATRC), AngioDynamics (ANGO), Alphatec (ATEC), Accuray (ARAY), Fc Global Realty (FCRE), Navidea Biopharmaceuticals (NAVB), Baxter International (BAX), Becton Dickinson and (BDX), Boston Scientific (BSX) and Cardiovascular Systems (CSII).

Based on aggregate information from My MarketBeat watchlists, some companies that other IDEXX Laboratories investors own include NVIDIA (NVDA), Paypal (PYPL), Alibaba Group (BABA), Netflix (NFLX), Adobe (ADBE), Mastercard (MA), Intuitive Surgical (ISRG), Home Depot (HD), Micron Technology (MU) and Walt Disney (DIS).

IDEXX Laboratories' stock is owned by a number of of retail and institutional investors. Top institutional investors include State Street Corp (4.40%), Blair William & Co. IL (1.80%), Principal Financial Group Inc. (1.39%), Franklin Resources Inc. (1.19%), Bank of America Corp DE (0.89%) and Bank of New York Mellon Corp (0.83%). Company insiders that own IDEXX Laboratories stock include Brian P Mckeon, Bruce L Claflin, Daniel M Junius, Giovani Twigge, Jacqueline Studer, Jay Mazelsky, Jonathan W Ayers, Lawrence D Kingsley, M Anne Szostak, Michael Lane, Rebecca M Henderson, Sophie V Vandebroek and William T End. View Institutional Ownership Trends for IDEXX Laboratories.

IDXX stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, Marshall Wace North America L.P., Skandinaviska Enskilda Banken AB publ , Massachusetts Financial Services Co. MA, MERIAN GLOBAL INVESTORS UK Ltd, MERIAN GLOBAL INVESTORS UK Ltd, Los Angeles Capital Management & Equity Research Inc. and First Trust Advisors LP. Company insiders that have sold IDEXX Laboratories company stock in the last year include Brian P Mckeon, Giovani Twigge, Jacqueline Studer, Jay Mazelsky, Jonathan W Ayers, M Anne Szostak, Michael Lane, Rebecca M Henderson and Sophie V Vandebroek. View Insider Buying and Selling for IDEXX Laboratories.

IDXX stock was purchased by a variety of institutional investors in the last quarter, including KBC Group NV, Robeco Institutional Asset Management B.V., Beacon Investment Advisory Services Inc., State Street Corp, Credit Suisse AG, Bank of Montreal Can, Great Diamond Partners LLC and Duality Advisers LP. Company insiders that have bought IDEXX Laboratories stock in the last two years include Bruce L Claflin and Lawrence D Kingsley. View Insider Buying and Selling for IDEXX Laboratories.

Shares of IDXX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of IDXX stock can currently be purchased for approximately $288.78.